Histogenics Corporation Provides NeoCart® Phase 3 Clinical Trial Enrollment Update
24 oct. 2016 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Ring the Nasdaq Stock Market Closing Bell
13 oct. 2016 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces Addition of Dr. Lawrence Bonassar of Cornell University to Its Scientific Advisory Board
06 oct. 2016 16h05 HE
|
Histogenics Corporation
- Company Adds Additional Leader in Tissue Engineering and Biomechanics -- Additional NeoCart® Biomechanical Data Presented in Conjunction with Cornell University - WALTHAM, Mass., Oct. 06, 2016 ...
Histogenics Corporation Closes $30.0 Million Private Placement
29 sept. 2016 16h05 HE
|
Histogenics Corporation
WALTHAM, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Present at the 2016 Cell & Gene Meeting on the Mesa
26 sept. 2016 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces $30.0 Million Private Placement
16 sept. 2016 06h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
31 août 2016 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results
11 août 2016 06h30 HE
|
Histogenics Corporation
- NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Increasing Year-End 2016 Enrollment Guidance to 190 to 200 patients...
Histogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016
28 juil. 2016 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal...
Histogenics Corporation to Present at the Canaccord Genuity Growth Conference
27 juil. 2016 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...